I'm pleased to report our long-term strategy and business positioning continued to deliver solid results as seen in Q2, where we experienced strong earnings growth and a stable revenue performance.
By segment, North America revenues were up 1.3%, positively impacted by the women's health analgesics, Oral Care and ear and eye care categories, partially offset by lower cough and cold and GI shipments at certain categories we participate in face declines in incidence levels and usage rates related to COVID-19.